Fennec Pharmaceuticals Inc. (TSE:FRX - Free Report) - Investment analysts at Wedbush dropped their FY2025 EPS estimates for shares of Fennec Pharmaceuticals in a report released on Thursday, November 7th. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company will post earnings per share of $0.07 for the year, down from their previous estimate of $0.08. The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is $0.60 per share. Wedbush also issued estimates for Fennec Pharmaceuticals' FY2026 earnings at $3.12 EPS.
Fennec Pharmaceuticals (TSE:FRX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported C($0.27) earnings per share for the quarter, missing analysts' consensus estimates of C$0.08 by C($0.35). Fennec Pharmaceuticals had a net margin of 5.59% and a negative return on equity of 1,005.59%. The company had revenue of C$9.94 million during the quarter, compared to the consensus estimate of C$18.67 million.
Fennec Pharmaceuticals Stock Down 4.7 %
Shares of FRX stock traded down C$0.28 during trading on Monday, reaching C$5.70. The company's stock had a trading volume of 1,219 shares, compared to its average volume of 1,851. The business has a fifty day moving average price of C$6.61 and a 200-day moving average price of C$8.37. The company has a quick ratio of 10.17, a current ratio of 8.02 and a debt-to-equity ratio of 1,040.68. The company has a market cap of C$155.95 million, a price-to-earnings ratio of 59.80 and a beta of 0.25. Fennec Pharmaceuticals has a one year low of C$5.70 and a one year high of C$15.43.
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Featured Articles
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
